8.15
+0.385(+4.96%)
Currency In USD
Address
180 North LaSalle Street
Chicago, IL 60601
United States of America
Phone
844 445 5704
Website
Sector
Healthcare
Industry
Biotechnology
Employees
394
First IPO Date
October 14, 2021
| Name | Title | Pay | Year Born |
| Mr. John P. Shannon | Chief Executive Officer & Director | 1.07M | 1962 |
| Mr. Steven M. Pieper | Chief Financial Officer | 747,017 | 1978 |
| Ms. Beth P. Hecht J.D. | Chief Legal Officer & Corporate Secretary | 767,825 | 1964 |
| Mr. Kevin McCulloch | President & Chief Operating Officer | 777,048 | 1964 |
| Mr. Paul R. Edick J.D. | Senior Advisor | 2.6M | 1956 |
| Dr. Anh Nguyen M.B.A., M.D. | Chief Medical Officer | 0 | 1975 |
| Ms. Allison Wey | Senior Vice President of Investor Relations & Corporate Communications | 0 | N/A |
| Mr. Brian Conner | SVice President of Quality and Chief Compliance & Risk Officer | 0 | N/A |
| Ms. Kendal Korte | Senior Vice President of Human Resources | 0 | N/A |
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.